Ganirelix

Mechanism

Another GnRH antagonist used in IVF to prevent premature ovulation, similar to cetrorelix. It immediately blocks the body's GnRH signal, suppressing LH and FSH without the initial hormone surge seen with GnRH agonists. Given as a daily subcutaneous injection during fertility stimulation cycles.

Effects

**Reproductive System (Tier 1 — FDA-approved):** Competitive antagonist at pituitary GnRH receptors. Rapidly and reversibly suppresses LH and FSH secretion within 4-8 hours of injection. Prevents premature LH surges during controlled ovarian hyperstimulation (COH) in IVF cycles. Does NOT cause the initial "flare" effect seen with GnRH agonists like leuprolide — suppression is immediate. LH suppression is dose-dependent: 0.25mg/day maintains LH below surge threshold in >95% of patients. FSH suppression is partial, allowing continued follicular development with exogenous gonadotropins. **Endocrine System (Tier 1):** Suppresses endogenous LH by 74% and FSH by 32% within 4 hours at standard 0.25mg dose. Estradiol levels are NOT directly suppressed — they continue to rise with exogenous FSH stimulation. Progesterone remains appropriately low pre-trigger. Recovery of pituitary function occurs within 48 hours of last dose (much faster than depot GnRH agonists which take weeks). **Ovarian Response (Tier 1):** In the flexible GnRH antagonist protocol, ganirelix is started when lead follicle reaches 14mm or estradiol exceeds 300 pg/mL (typically cycle day 5-7 of stimulation). This "late start" allows natural FSH-driven recruitment before suppression, often resulting in fewer but higher-quality oocytes compared to long agonist protocols. Lower risk of OHSS vs. long agonist protocols due to shorter suppression window and ability to use GnRH agonist trigger. **Metabolic/Systemic (Tier 1):** Minimal systemic side effects. No hot flashes or estrogen-deprivation symptoms (unlike depot agonists). Injection site reactions (redness, swelling) in ~10-15% of patients. No clinically significant effect on lipids, bone density, or glucose metabolism during short-term IVF use.

Practitioner Guide

**Standard IVF Protocol (Flexible Antagonist):** - Start ganirelix 0.25mg SC daily when: (a) lead follicle >= 13-14mm, OR (b) estradiol >= 300 pg/mL, OR (c) fixed day 5-6 of stimulation - Continue daily until trigger day (inclusive — last dose on morning of trigger day or evening before) - Typical duration: 4-6 days of ganirelix use - Administer at same time daily (consistency matters — LH can escape with >30hr gap between doses) - Compatible with all trigger options: HCG trigger (10,000 IU), dual trigger (HCG + GnRH agonist), or GnRH agonist-only trigger **Advantages Over Long Agonist (Lupron) Protocol:** - Shorter stimulation time (average 1-2 fewer days of gonadotropins) - Lower total gonadotropin consumption (cost savings) - Allows GnRH agonist trigger — dramatically reduces OHSS risk (critical for high responders/PCOS patients) - No 2-week downregulation phase — patients prefer the shorter protocol - Comparable pregnancy rates in most populations (slight advantage of long agonist in poor responders is debated) **When Fertility Specialists Choose Ganirelix Over Lupron:** - PCOS patients or high responders (AMH > 4, AFC > 20) — OHSS prevention is priority - Patients who want shorter protocol with fewer injections total - Freeze-all cycles (agonist trigger + freeze all is standard of care in high-risk OHSS) - Donor egg cycles (most programs now use antagonist protocol for donors) **When Specialists Still Prefer Long Agonist:** - Poor responders who need maximum follicular synchrony - Patients with prior premature LH surge on antagonist protocol (rare) - Some endometriosis patients (longer suppression may improve implantation environment) **Practical Tips:** - Inject in abdomen (rotating sites), avoid within 2 inches of navel - Can be given at same time as gonadotropins (different site) - Store in refrigerator; allow to reach room temperature before injection to reduce sting - If patient forgets a dose, inject ASAP and resume normal schedule — monitor LH at next visit

Evidence

• Ganirelix and the prevention of premature luteinizing hormone surges

  (2023) — Elsevier BV — PMID: 10.1016/j.xfre.2023.02.009

  Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone surges in assisted reproduction. A daily dose of 0.25 mg is effective in preventing premature luteinizing hormone surges and yields a high ongoing pregnancy rate per started cycle. Ganirelix has several advantages over long GnRH agonist treatment, including immediate reversibility of drug effects, reduced patient burden, and lower risk of ovarian hyperstimulation syndrome.

  moderate

• Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study

  Han et al. (2022) — J Obstet Gynaecol — PMID: 35254199

  In 236 women undergoing IVF, a new ganirelix acetate prefilled syringe showed comparable premature-LH-surge suppression, oocyte retrieval, embryo quality, fertilization outcomes, and safety versus Orgalutran.

  moderate

• Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment

  Messinis IE et al. (2005) — Hum Reprod — PMID: 16037104

  In 73 women undergoing IVF/ICSI with recombinant FSH, daily and alternate-day ganirelix produced similar hormone trends and similar low luteinization rates, while alternate-day dosing used less antagonist. The trial was not powered for pregnancy outcomes.

  moderate

• Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.

  Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT, Schoolcraft W, Shapiro DB, North American Ganirelix Study Group. (2001) — Fertil Steril — PMID: 11163814

  Ganirelix acetate was compared to leuprolide acetate in women undergoing controlled ovarian hyperstimulation. The study found similar pregnancy rates between the two groups, but with fewer injection site reactions in the ganirelix group.

  strong

• Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.

  Borm G, Mannaerts B. (2000) — Hum Reprod — PMID: 10875855

  Ganirelix treatment resulted in similar outcomes to buserelin in women undergoing ovarian stimulation for IVF or ICSI, with a shorter duration of treatment (5 days vs 26 days) and lower incidence of ovarian hyperstimulation syndrome (2.4% vs 5.9%).

  strong

• Ganirelix

  (2000) — Springer Science and Business Media LLC — PMID: 10.2165/00003495-200059010-00007

  Ganirelix effectively inhibited LH surges during controlled ovarian stimulation, achieving a vital pregnancy rate per embryo transfer of 40.3% at weeks 5 to 6 with a 0.25 mg/day dosage.

  strong

Research Summary

**Tier 1 — FDA-approved, Phase III RCTs:** - FDA approved 1999 for prevention of premature LH surges in women undergoing COH for IVF - Pivotal trials: North American (n=313) and European (n=730) phase III trials showed comparable pregnancy rates to leuprolide long protocol with significantly reduced OHSS incidence - Ganirelix vs. cetrorelix: head-to-head studies show no significant difference in live birth rates, OHSS rates, or oocyte yield (both are effective GnRH antagonists) - Cochrane meta-analysis (2016, 73 RCTs, n=12,212): GnRH antagonist protocols have significantly lower OHSS risk (OR 0.61) with no significant difference in live birth rate vs. long agonist protocols **Tier 2 — Established Clinical Evidence:** - Flexible vs. fixed-start antagonist: flexible protocol (start at 14mm follicle) shows comparable outcomes with 0.6 fewer days of antagonist use on average - Dual trigger (low-dose HCG + GnRH agonist) after antagonist protocol: emerging standard for balancing OHSS risk with adequate corpus luteum support - In poor responders: some evidence that micro-dose Lupron flare or mild stimulation with late antagonist start may improve oocyte yield **Tier 3 — Emerging/Experimental:** - Off-label use in male contraception studies (combined with testosterone — exploratory) - Investigation in endometriosis symptom management (short-course antagonist without add-back) - Potential role in fertility preservation urgency protocols ("random start" IVF with antagonist)